Clinical Trials Insight: 700036982
Phase of Trial: Phase I
Latest Information Update: 12 May 2009
At a glance
- Drugs PSN 821 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- 12 May 2009 Results reported in an OSI Pharmaceuticals media release. Results are also expected to be presented together with the second phase I trial (trial profile 700044736) at a scientific session.
- 12 May 2009 According to an OSI Pharmaceuticals media release, data from this trial was used to support progression of PSN821 into a 14-day trial (see trial profile 700044736).
- 12 May 2009 Status changed from recruiting to completed, according to an OSI Pharmaceuticals media release.